MX388141B - EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III. - Google Patents
EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III.Info
- Publication number
- MX388141B MX388141B MX2017012641A MX2017012641A MX388141B MX 388141 B MX388141 B MX 388141B MX 2017012641 A MX2017012641 A MX 2017012641A MX 2017012641 A MX2017012641 A MX 2017012641A MX 388141 B MX388141 B MX 388141B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- iii
- fatty acid
- acid derivatives
- polyunsaturated fatty
- Prior art date
Links
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 title 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 abstract 2
- 108010056301 Apolipoprotein C-III Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2015/001316 WO2016156912A1 (en) | 2015-04-01 | 2015-04-01 | Use of thia oxo compounds for lowering apo c3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012641A MX2017012641A (es) | 2018-06-06 |
| MX388141B true MX388141B (es) | 2025-03-19 |
Family
ID=53879725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012641A MX388141B (es) | 2015-04-01 | 2015-04-01 | EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180110747A1 (enExample) |
| JP (1) | JP2018510206A (enExample) |
| KR (1) | KR20180010181A (enExample) |
| AU (1) | AU2015389862B2 (enExample) |
| MX (1) | MX388141B (enExample) |
| RU (1) | RU2705991C2 (enExample) |
| WO (1) | WO2016156912A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016256552B2 (en) | 2015-04-28 | 2021-04-01 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| KR20210015883A (ko) | 2018-05-23 | 2021-02-10 | 노스씨 테라퓨틱스 비.브이. | 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 |
| JP2023554524A (ja) | 2020-12-22 | 2023-12-27 | ノースシー セラピューティクス ベスローテン フェンノートシャップ | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101783817B1 (ko) * | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| SG10201509127YA (en) * | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| KR20150028233A (ko) * | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-３ 지방산의 조성물 |
| US11351139B2 (en) * | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
-
2015
- 2015-04-01 WO PCT/IB2015/001316 patent/WO2016156912A1/en not_active Ceased
- 2015-04-01 US US15/562,554 patent/US20180110747A1/en not_active Abandoned
- 2015-04-01 JP JP2017552093A patent/JP2018510206A/ja active Pending
- 2015-04-01 AU AU2015389862A patent/AU2015389862B2/en active Active
- 2015-04-01 MX MX2017012641A patent/MX388141B/es unknown
- 2015-04-01 KR KR1020177031665A patent/KR20180010181A/ko not_active Ceased
- 2015-04-01 RU RU2017137960A patent/RU2705991C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015389862A1 (en) | 2017-11-23 |
| US20180110747A1 (en) | 2018-04-26 |
| RU2705991C2 (ru) | 2019-11-13 |
| JP2018510206A (ja) | 2018-04-12 |
| MX2017012641A (es) | 2018-06-06 |
| AU2015389862B2 (en) | 2021-04-15 |
| KR20180010181A (ko) | 2018-01-30 |
| RU2017137960A3 (enExample) | 2019-05-06 |
| WO2016156912A1 (en) | 2016-10-06 |
| RU2017137960A (ru) | 2019-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377255B (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| MX383051B (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos. | |
| HRP20221536T1 (hr) | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina | |
| EA201491484A1 (ru) | Фармацевтические композиции, содержащие диметилфумарат | |
| NZ709486A (en) | Solid solution compositions and use in chronic inflammation | |
| CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| DOP2016000270A (es) | Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpa | |
| MX385158B (es) | Derivados indol para uso en medicina. | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| NZ720174A (en) | Ionizable cationic lipid for rna delivery | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| ECSP13012362A (es) | Derivados de indolizina, su procedimiento de preparación | |
| MX2015014746A (es) | Derivados de dolastatina 10 y auristatinas. | |
| EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
| MX373622B (es) | Mezclas de compuestos, su preparación y sus usos. | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
| MY170076A (en) | Methods of treatment using lipid compounds | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| DK3082795T3 (da) | Sammensætninger af omega 3 fedtsyrer til behandling af sygdomme, der involverer skader på nervesystemet | |
| MX390011B (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| RU2016116036A (ru) | Производное циклического амина и его фармацевтическое применение | |
| EA201590315A1 (ru) | Средства и способ лечения солидных опухолей | |
| MX2017012641A (es) | Uso de compuestos tia oxo para disminuir apo c3. |